Emerging Therapeutic Strategies for Graves' Disease: Current Advances and Future Perspectives.

Graves' Disease (GD) is the leading cause of autoimmune hyperthyroidism and is still considered a challenging clinical condition. Antithyroid drugs, radioactive iodine, and thyroidectomy have long been used as main treatments. These approaches are generally effective in restoring euthyroidism and controlling thyroid function, even if they cannot target the underlying autoimmune mechanisms implicated in the disease. As a result, relapses after medical therapy remain frequent, whereas definitive treatments often lead to permanent hypothyroidism and the need for a lifelong thyroid hormone replacement. New results in the study of immunological mechanisms underlying GD have led to the development of targeted therapies. Targeted strategies are based on key components of disease pathogenesis, such as the thyrotropin receptor, B lymphocytes, co-stimulatory immune pathways, the insulin-like growth factor-1 receptor, and neonatal Fc receptors. A pivotal step in the development of targeted mechanism-based therapies for GD has been reached with the approval of teprotumumab. Several targeted therapies have been evaluated, such as K1-70, iscalimab, rituximab, tocilizumab, batoclimab, and the antigen-specific immunotherapy ATX-GD-59. This review highlights the limitations of currently available treatment options by examining the most promising emerging therapies and the future horizons for precision medicine in GD. Advances in the therapeutic landscape offer disease-modifying strategies that could complement and potentially replace current treatment strategies.